This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2028 Remove Biosimilars Remove Diabetes
article thumbnail

Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData

Express Pharma

AUGUST 22, 2023

Lilly’s strong market capitalisation growth over Q2 was attributed to its diabetes drug Mounjaro, a synthetic peptide that reported $980 million in global sales, according to GlobalData’s Pharmaceutical Intelligence Center Drugs Database. per cent increase in market capitalisation.” billion by 2029, according to GlobalData’s Drugs Database.

Biosimilars 88
Biosimilars Diabetes 88
article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

AUGUST 21, 2023

Its diabetes treatment Mounjaro led this outcome. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. billion in Q2 2023.

Biosimilars 98
Biosimilars Diabetes Vaccines 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 11,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024